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Abstract
Cochleates are phospholipid-calcium precipitates derived from the interaction of anionic lipid vesicles with divalent cations.
Proteoliposomes from bacteria may also be used as a source of negatively charged components, to induce calcium-
cochleate formation. In this study, proteoliposomes from V. cholerae O1 (PLc) (sized 160.761.6 nm) were transformed into
larger (16.364.6 mm) cochleate-like structures (named Adjuvant Finlay Cochleate 2, AFCo2) and evaluated by electron
microscopy (EM). Measurements from transmission EM (TEM) showed the structures had a similar size to that previously
reported using light microscopy, while observations from scanning electron microscopy (SEM) indicated that the structures
were multilayered and of cochleate-like formation. The edges of the AFCo2 structures appeared to have spaces that allowed
penetration of negative stain or Ovalbumin labeled with Texas Red (OVA-TR) observed by epi-fluorescence microscopy. In
addition, freeze fracture electron microscopy confirmed that the AFCo2 structures consisted of multiple overlapping layers,
which corresponds to previous descriptions of cochleates. TEM also showed that small vesicles co-existed with the larger
cochleate structures, and in vitro treatment with a calcium chelator caused the AFCo2 to unfold and reassemble into small
proteoliposome-like structures. Using OVA as a model antigen, we demonstrated the potential loading capacity of a
heterologous antigen and in vivo studies showed that with simple admixing and administration via intragastric and
intranasal routes AFCo2 provided enhanced adjuvant properties compared with PLc.
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Introduction
Cochleates (Co) are phospholipid-calcium precipitates derived
from the interaction of anionic lipid vesicles with divalent cations
such as calcium. They have a defined multilayered structure
consisting of a solid, lipid bilayer sheet rolled up in a spiral.
Papahadjopoulos et al., 1975 [1] first described Co as an
intermediate in the preparation of large unilamellar liposomes.
Since then, Co have been used to deliver proteins, peptides and
DNA for vaccine applications by oral and nasal routes [2]. Co
have a lot of advantages over other particulate structures such as
liposomes, tubules, or ribbons because they are thermodynami-
cally more stable and permit a high loading of components with
different physicochemical properties [3]. Thus, hydrophilic and
hydrophobic molecules can be accommodated between the lipid
bilayers and inner hydrophobic space, respectively [3]. A novel
and proprietary strategy developed by the Finlay Institute employs
proteoliposomes (PL) extracted from bacteria as a source of
negatively charged molecules including phospholipids, proteins,
and lipopolysaccharides, to induce cochleate formation in the
presence of divalent cations [4]. The Adjuvant Finlay Cochleate 1
(AFCo1) derived from Neisseria meningitidis serogroup B proteolipo-
somes (AFPL1) is more stable and immunogenic when adminis-
tered via the nasal route compared with the proteoliposomes [5].
We have expanded the Co formation strategy to other microor-
ganisms such as Vibrio cholerae to develop a novel mucosal
formulation against this and related enteric pathogens. This was
achieved by preparing proteoliposomes from V. cholerae O1 El Tor
Ogawa, C7258 strain (called PLc) and then transforming them
into new tubular structures designated AFCo2 [6].
The aim of this paper was to evaluate the molecular
organization of AFCo2, using electron microscopy to gain a
greater understanding of the formation of the membranes in
AFCo2, to evaluate the interaction of AFCo2 with a heterologous
antigen (OVA) and to assess the immune response induced when
the antigen was admixed and administered via intragastric and
nasal routes.
Materials and Methods
Dialysis rotary method for producing cochleates
AFCo2 from V. cholerae were obtained as described by Acevedo
et al. (2009) [6]. Briefly, we re-suspended and adjusted PLc to
1 mg/mL (protein content) in a buffer containing 30 mmol/L
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tris(hydroxymethyl)aminomethane (Tris) and 1.5% (w/v) sodium
deoxycholate (DOC). AFCo2 formation was performed by
detergent elimination and Ca2+ incorporation using rotary dialysis
against a wash buffer containing 30 mmol/L Tris, 100 mmol/L
NaCl and 5 mmol/L CaCl2 at pH 7.4. Five to six washes were
carried out at 2 hourly intervals. As visual precipitation occurred
during the course of processing, supplementary observations were
made by light microscopy using an Opton Standard 25
microscope and the size of the particles determined using a
gradation scale on the ocular lens.
Negative Staining and Transmission Electron Microscopy
(TEM)
Sample preparations were carried out by Dr Laurence Tetley
(Glasgow University, UK) as follows: Formvar/Carbon-coated
200 mesh copper grids were glow discharged. Cochleate samples
were resuspended in 30 mM Tris buffer and dried with filter paper
to a thin layer onto the hydrophilic support film. Twenty
microlitres of 1% (v/v) aqueous methylamine vanadate stain
(Nanovan; Nanoprobes, Stony Brook, NY, USA) was applied and
excess moisture removed with filter paper. Dried samples were
imaged with a LEO 912 energy filtering transmission electron
microscope operating at 120 kV. Contrast enhanced, zero-loss
energy filtered digital images were recorded with a 14 bit/2 K
Proscan CCD camera.
Scanning electron microscopy (SEM)
SEM was carried out as described by Qu et al. [7]. Briefly,
samples were dissolved in the Tris-Ca wash buffer and frozen on
glass coverslips in liquid propane/isopentane (3:1 v/v), then
lyophilised (overnight at 280uC) mounted on specimen stubs with
conductive copper tape prior to applying a 20 nm gold/palladium
coating with a Polaron SC515 sputter coater using a Peltier cold
stage. SEM was performed on a JSEM 6400 instrument (JEOL
Ltd, UK) with an ADDA3 digital interface and 2 K format images
were recorded operating at 6 or 3 kV to enhance surface imaging.
Freeze-fracture electron microscopy (FFEM)
Sample procedures were carried out as described by Qu et al.
[7]. Briefly, samples were sandwiched between two copper support
plates (Bal-Tec AG, Balzers, Lichtenstein) and snap-frozen by
plunging them into a cryogenic mixture of propane/isopentane
3:1 (v/v) at 2190uC. These were then stored at 2150uC.
Fracturing was carried out at 2100uC at 1026 torr with the
fracture face replicated with platinum/carbon (PtC, Agar Scien-
tific, UK) and carbon coated at a 90u angle to the surface. Acetone
was used to clean the replicates and they were collected onto a
mesh (100 grid bars/in), dried and examined in a LEO 912 energy
filtering transmission electron microscope operating at 80 kV.
Contrast enhanced, zero-loss energy filtered digital images were
recorded with a 14 bit/2 K Proscan CCD camera.
Fluorescence experiments and sample preparation
AFCo2 and PLc were mixed separately with OVA labelled
Texas Red (OVA-TR) (Invitrogen, Ltd. UK) for 10 min with
agitation. The formulations were washed three times by ultra-
centrifugation (10 000 g61 h) using an Amicon 100 000 kDa
filtration unit to eliminate unbound OVA-TR. Adsorbed OVA on
the surface of the structures was removed by sonication and then
washed again three times in the Amicon unit to eliminate non-
adsorbed OVA-TR. The structures were observed using a Zeiss
Axioplan 2 epifluorescence microscope (Carl Zeiss Jena GmbH,
Jena, Germany) and imaged with a Canon 350D DSLR camera.
Filtrates and pellets were analyzed with a fluorescence microplate
reader (SpectraMax M5, Molecular Devices, Corp, US) at 615 nm
and 596 nm. AFCo2 pellets were treated with EDTA (50 mM) as
described in the next section. The loading average of OVA-TR
was calculated as: OVA-TR [Pellet+Filtrate]/OVA-TR [Pel-
let]6100, using an OVA calibration curve.
Observation of AFCo2 unfolding and sample preparation
EDTA solutions ranging from 5 to 50 mM were incubated with
0.05 mg/mL AFCo2. Briefly, AFCo2 samples were centrifuged at
3000 g for 5 min and the supernatant discarded. The pellet was
re-suspended up to the same volume with the different EDTA
concentrations. The number of unfolding structures was evaluated
by light microscopy at 4006magnification using a Reichert-Jung
Polyvar microscope and recorded using a JVC MicroCam camera
coupled to the microscope.
Photon correlation spectroscopy (PCS)
Particle size, polydispersion and zeta potential of the samples
were analyzed using a Malvern Instruments Zetasizer Nano ZS
operated at 25uC using triplicate readings and a 2 min equilibra-
tion time.
Immunization and sample collection
Groups of female BALB/c mice (6–8 weeks old, CENPALAB,
Cuba) were immunized intranasally or intragastrically with
AFCo2 or PLc (100 mg per dose per mouse). These mice are an
established model used in our laboratory to evaluate cochleate
adjuvant activity [6]. Mice received three administrations by
intragastric (i.g) gavage (200 mL) or intranasal (i.n) instillations
(10 mL per nostril) once a week (0, 7 and 14). Placebo groups were
also immunized with 20 mL (10 mL per nostril) of phosphate
buffered saline (PBS) by the i.n route or 200 mL by the i.g route.
Mucosal (saliva and faeces) and sera samples were taken at 7 and
14 days after the last immunization, respectively. Prior to
immunization, samples were also collected and prepared as
described previously [6]. Animals were housed at the Finlay
Institute animal facility and all experiments were performed with
the approval of the Finlay Institute Ethical Committee.
Enzyme-linked immunosorbent assay (ELISA) for PLc
specific or OVA specific IgA, IgG and IgG isotypes
Specific IgG, IgG1 and IgG2a anti-PLc antibodies in serum
samples and IgA anti-PLc antibodies in saliva or faeces were
measured by indirect ELISA using Nunc-Immuno MaxiSorp 96-
well plates. Plates were coated with PLc (100 mL per well) at 5 mg/
mL or OVA at 5 mg/mL (100 mL per well) in PBS buffer
(0.15 mol/L, pH 7.3) at 4uC overnight, and blocked with 1% (w/
v) BSA in PBS (blocking solution) for 1 h at room temperature.
Serum samples were serially diluted (1:50 to 1:3600) and saliva (1:2
to 1:32) in blocking solution and incubated for 1 h at 37uC. Anti-
mouse IgG or IgA peroxidase-conjugated antibodies (Sigma, USA)
were added (100 mL per well) at 1:2500 dilution in blocking
solution and incubated for 1 h at 37uC. For IgG isotypes anti-
mouse IgG biotinylated antibody (1:1000) were used (Sigma,
USA). Bound antibodies were detected with 100 mL per well of the
substrate-chromogen mixture (o-phenylenediamine and hydrogen
peroxide in citrate-phosphate buffer, pH 5). The reaction was
stopped by adding 50 mL of sulphuric acid at 2 mol/L and optical
density at 492 nm was measured using a microplate reader
(Titertek, Multiskan Plus, Germany). All incubation steps were
followed by three washes with PBS containing 0.05% Tween-20
(v/v). Positive antibody titers were defined as the highest dilution
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giving an OD value that was twice that of negative controls (pre-
immune serum, saliva or faeces). Antibody measurements were
expressed as the logarithm of the geometric mean of three different
experiments 6 SEM.
Vibriocidal antibody assay
Serum vibriocidal antibodies were determined as described
previously [6]. Briefly, 50 mL of two-fold dilutions of decom-
plemented sera in PBS were mixed with 50 mL of a V. cholerae
VC12 (serotype Ogawa) suspension containing 108 CFU/mL in
PBS supplemented with 2% (w/v) guinea pig complement and
placed in a 96-well microtitre plate. The mixture was incubated
for 1 h at 37uC and subsequently supplemented with 100 mL of
Brain Heart Infusion Broth containing 2% (w/v) dextrose and
0.02% (w/v) bromocresol purple. The plates were incubated at
37uC for 3 h. Bacterial growth was determined by a colour change
of the medium, which indicated bacterial dextrose consumption.
During the bactericidal reaction the serum dilution in the first
column of the plate was 1:20 and in the last one was 1:10240. The
vibriocidal antibody titer was calculated as the inverse of the
highest dilution of serum causing complete inhibition of bacterial
growth (no change of colour in the medium). The results were
expressed as the logarithm of the geometric mean of three different
experiments 6 SEM.
Statistical Analysis
All the statistical analyses were performed using GraphPad
Software Inc, La Jolla CA, USA. Statistical significance of the
variance between multiple groups was calculated with one-way
ANOVA, followed by a Tukey’s multiple comparison test
(statistical significance, p,0.05). The experimental data was first
subjected to a Kolmogorov-Smirnov normality test with Dallal-
Wilkinson-Lillie for p-value.
Results
Transformation of PLc into AFCo2
PLc structures of approximately 160.761.6 nm in size were
transformed into AFCo2 using a dialysis rotary method [6]. The
process was characterized by a slow transformation in the visual
appearance of the solution from a colourless solution (PLc) to a
milky white suspension (Figure 1A). Figure 1B shows a micrograph
of the AFCo2 observed by light microscopy and Figure 1C the size
distribution, 16.364.6 mm, determined using a gradation scale on
the microscope.
Electron microscopy reveals cochleate structures
Micrographs obtained by TEM show that the PLc (Figure 2A)
changed at supramolecular level in a calcium environment and
became transformed into AFCo2 structures (Figure 2B). It is
Figure 1. AFCo2 formation. (A) White milky suspension (AFCo2) obtained after calcium interaction with a solution of PLc, (B) AFCo2 observed by
light microscopy with an Opton Standard 25 microscope (magnification 6400), (C) distribution percentage (82.6%) of AFCo2 with a length of
16.364.6 mm measured using a graduated scale on the ocular lens of the microscope.
doi:10.1371/journal.pone.0046461.g001
Figure 2. Supramolecular transformation of PLc in AFCo2, observed by TEM. (A) Negatively stained PLc (610000 magnification), (B) AFCo2,
tubular structure observed using negative stain (61000) [arrows indicate the distribution of stain inside the AFCo2 structure], (C) AFCO2 and vesicles
(arrows) co-existing (62000).
doi:10.1371/journal.pone.0046461.g002
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noteworthy that the PLc bilayer was not permeable to negative
staining, whereas the stain diffused to some extent into the AFCo2.
However, this diffusion was not homogeneously distributed. These
micrographs also reveal that the AFCo2 structures had widths in
the range of 2 to 4.5 mm.
Figure 3A (SEM micrograph) shows that AFCo2 consist of
multiple overlapping layers. Magnification of Figure 3B reveals
hollows or pores found mainly at the edges of the structures.
Micrographs obtained by FFEM show that AFCo2 appear to be
compact cylinders and confirm previous SEM results where
multiple fractured layers are observed (Figure 4A). The typical
spiral organization of the cochleates is identifiable in Figure 4B
where curvature in the different layers forming the AFCo2 can be
observed.
Internalization and loading of a fluorescent probe in
AFCo2
In this experiment the OVA-TR was associated with AFCo2
after mixing (Figure 5A), but little or no fluorescence was observed
from the sample of OVA-TR mixed with PLc (Figure 5D).
Loading experiments showed 46% of OVA-TR was entrapped in
the AFCo2, however less than 2% of the OVA-TR was calculated
to be associated to PLc. Additionally, AFCo2 could be disrupted
by sonication (Figure 5B) and any unbound OVA-TR removed by
washing. Figure 5C shows that the disrupted AFCo2 still emitted
an OVA-TR signal; the higher intensity coming from within the
structure. Finally, zeta potential measurements revealed that the
AFCo2 surface had a slightly negative charge 27.2560.25 mV
compared with PLc, which had a charge of 231.260.42 mV.
Cochleates unfold into small vesicles in the presence of
EDTA
Different concentrations of EDTA ranging from 1 to 50 mM
were used to sequestrate calcium from the AFCo2 in order to
unfold the structure. Table 1 shows that the best concentrations for
unfolding 50 mg (by protein content) per mL of AFCo2 were 25
and 50 mM EDTA. The measurements were obtained using light
microscopy; the results show the number of particles observed in
64 fields using a Neubauer chamber. A recording was made to
show a cochleate structure unfolding under EDTA action (Video
S1, supporting information). Photon correlation spectroscopy
analysis also revealed that EDTA treated AFCo2 re-formed into
vesicles with a size about 50368.0 nm and a polydispersion index
of 0.3260.04. Figure 6 shows the unfolding effect of 25 mM
EDTA in AFCo2. The tubular structure begins to shrink in the
first 20 seconds before finally disappearing.
Evaluation of immune response induced by mucosal
administration of AFCo2
Female BALB/c mice were immunised via the i.g or i.n route
with 100 mg of AFCo2 or PLc using a three dose schedule (0, 7
and 14 days). Since PLc are transformed into AFCo2, both
structures contain the same V. cholerae antigens. ELISAs were
carried out to detect specific anti-PLc antibodies in mucosal (saliva
and faeces) and systemic (sera) collected samples. Table 2 shows
that mice were only responsive at mucosal level with AFCo2
administered by the i.g route. Intragastrically immunised mice
with PLc did not elicit any antibody response. However, mice
immunised with AFCo2 or PLc by the i.n route elicited similar
immune response (IgG and vibriocidal activity) in sera (p.0.05).
The IgG2a/IgG1 response in mice immunised with AFCo2 or
PLc was mixed although AFCo2 moved the balance toward the
induction of IgG2a (IgG2a/IgG1= 1.04) and PLc toward IgG1
(IgG2a/IgG1= 0.89) production. In addition, the anti-PLc IgA in
Figure 3. Scanning electron micrographs of AFCo2. (A) Tubular
and multilamellar structures observed at 61400 [multilamellarity is
indicated by white arrows], (B) the open end of the structure magnified
63300.
doi:10.1371/journal.pone.0046461.g003
Figure 4. Freeze fracture electron micrographs of AFCo2. (A)
Cylindrical shape of AFCo2 and black arrows point to the multiple layers
forming the structure, (B) Overlapping layers can be observed with a
curvature and disposition similar to the classic spiral pattern
characteristic of cochleate structures.
doi:10.1371/journal.pone.0046461.g004
Figure 5. Labeling AFCo2 and PLc with OVA-TR. (A) AFCo2
admixed with OVA-TR. The images were obtained with a coupled-
device camera linked to an epi-fluorescence microscope. After
sonication and ultrafiltration AFCo2+OVA-TR was analyzed by light
microscopy as shown in (B). The broken structure is a consequence of
the sonication process. (C) The same AFCo2 structure observed by epi-
fluorescence showing the distribution of the Ova-TR in AFCo2. (D)
PLc+OVA-TR observed by epi-fluorescence showing a lack of signal.
doi:10.1371/journal.pone.0046461.g005
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saliva and faeces were significantly higher in mice immunised
intranasally with AFCo2 (p,0.05) than in mice immunised with
PLc via the same route.
Evaluation of the immune response induced by i.n
administration of AFCo2 or PLc with OVA
OVA was admixed with AFCo2 (AFCo2 plus OVA) or PLc
(PLc plus OVA) and administered to BALB/c mice via the i.n
route. The effect of co-administration was evaluated taking into
consideration the anti-OVA IgA and IgG, as well as IgG subclass
response of specific antibodies elicited in mucosal (saliva and
faeces) and systemic (sera) samples, respectively. Table 3 shows
that saliva and faeces from mice intranasally immunised with
AFCo2 plus OVA had significantly (p,0.05) higher anti-OVA
IgA titres than from mice immunised only with OVA or PLc plus
OVA. Although, PLc plus OVA induced a significantly (p,0.05)
higher mucosal immune response (anti-OVA IgA in saliva and
faeces) compared with the response from mice immunised only
with OVA, anti-OVA IgG responses in mice immunised with
AFCo2 or PLc plus OVA were not statistically significant
(p.0.05). A mixed IgG2a/IgG1 response was observed in both
treatments (Table 3).
Discussion
Mucosal vaccination is considered an appropriate strategy to
combat emerging and re-emerging infectious diseases because of
the ability to induce both mucosal and systemic immune responses
[8]. Various strategies have been employed to improve immuno-
genicity and delivery of antigens to mucosal surfaces [9–10]. PLc
and AFCo2 are particulate structures derived from V. cholerae O1
with adjuvant and vaccine potential, although AFCo2 are more
immunogenic at the mucosal level than PLc when administered by
the intranasal route [6]. Different assemblies of antigens,
immunostimulators and components of both structures may be
responsible for this effect. AFCo2 have a micro-tubular structure
whereas PLc are nano proteoliposomes. AFCo2 have been
described as cochleates due to light microscopy observations [6].
However more evidence is needed to affirm this from a physical
and morphological point of view [1–3]. We have reported here
that the nanosized PLc may be transformed into tubular
microparticles of 16.364.6 mm in length (AFCo2) in a calcium
environment. AFCo2 form a milky white suspension, when
dissolved in a detergent buffer, which is presumably the result of
calcium interaction with the negative components of the PLc.
Measurements of the length of the structures observed by TEM
correspond with previous results [6] obtained by light microscopy
and reveals that the width of the AFCo2 are in the range of 2 to
4.5 mm (Figures 2B and 2C); this is much larger than the size
reported for cochleates obtained using ‘‘pure or synthetic lipids’’
[1–2]. The rotary dialysis method performed involves the removal
of detergent against a calcium chloride solution and the
transformation mechanism may be explained by competition
between removal of detergent from the detergent/phospholipids/
drug micelles and the condensation of bilayers by calcium [2].
Some research has been performed to observe the interactions that
occur in cochleates using synthetic or purified lipids [1–3].
However, cochleates obtained from bacterial proteoliposomes
have additional interactions resulting from the presence of LPS
and protein antigens that may have impact on the supramolecular
organization of the structure [4]. In particular, this may arise from
OmpU porin, a representative protein in PLc which has an
isoelectric point of 4.2 [6] and a negative charge at the neutral pH
(pH 7.4) at which AFCo2 is prepared. Additionally, the outer
membrane of V. cholerae contains negatively charged phospholipids
[11–12] that also point to PLc containing these types of structures.
TEM analysis revealed that negative staining penetrates into the
AFCo2, whereas PLc remained impermeable to vanadate
(Figures 2A and 2B). This may be explained by observations
made through SEM, since in Figure 3A, AFCo2 are presented as
multilamellar structures with porous edges (Figure 3B) that allowed
Figure 6. AFCo2 unfolding with EDTA. The micrographs represent stills of Video S1 (supporting information) that shows the unfolding process of
AFCo2 under the action of EDTA chelating agent (25 mM). AFCo2 starts to shrinks in the first 15 seconds and completely disappears at 25 seconds of
exposure with EDTA.
doi:10.1371/journal.pone.0046461.g006
Table 1. AFCo2 unfolding in the presence of EDTA.
EDTA [mM] Quantity of unfolded particles
1 +++
5 ++
10 +/2
25 -
50 -
AFCo2 was resuspended at a final protein concentration of 0.05 mg/mL with
buffer containing Tris 30 mM and EDTA ranging from 1 to 50 mM. The results
show the number of particles observed in 64 fields in a Neubauer chamber
using light microscopy. EDTA concentrations from 25 to 50 mM were suitable
for completely unfolding the AFCo2.
+++ more than 100 particles observed per view, ++ 40–80 particles, 2/+ 10–40
particles, - no particles.
doi:10.1371/journal.pone.0046461.t001
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negative stain and also larger macromolecules like OVA-TR
(.40 kDa) to enter. Fluorescence studies demonstrated that a
fraction of OVA-TR is incorporated inside the AFCo2 structure
after mixing. Epi-fluorescence studies showed that sonication
followed by a wash step did not eliminate OVA-TR associated
with the AFCo2 (Figure 5), suggesting that binding had occurred.
In addition, a considerable amount of the probe may have been
internalized into the AFCo2 structures, because in contrast to
undisrupted AFCo2, a higher signal intensity came from the
exposed section of the cochleates. Furthermore, loading experi-
ments confirmed that a high amount of labelled OVA was
entrapped within the AFCo2 and conversely, OVA-TR was not
observed in association with PLc (Figure 5D).
Several authors have proposed and demonstrated that cochle-
ates are compact structures and incorporation of drugs and
biological molecules occurs mainly during their formation [2–4].
However, AFCo2 derived from bacteria as well as AFCo1 [4] are
permeable to small molecules used to stain the samples, and also to
bigger molecules. Proteoliposome-derived cochleates, like AFCo1,
have been used as adjuvants with heterologous co-administered
antigens such as ovalbumin (OVA) [5]. The ultimate goal in
producing particulate adjuvants from V. cholerae O1 is to construct
a delivery system for antigens from other enteric pathogens in
order to develop a multiple vaccine candidate. Pe´rez et al. [5] have
observed that incorporation of OVA in Co from N. meningitidis
during the dialysis process or admixture of antigen with the ready-
made AFCo1 was feasible, and did not affect the immune response
induced against OVA. However, to date no studies have been
performed to evaluate the nature of interactions between AFCo1
and OVA. The capacity to load adjuvant-particles like AFCo2 or
AFCo1 by simple admixing with antigen may be significant in
epidemic settings where speed of vaccine manufacture is critical to
minimize resultant mortality and/or morbidity [8]. Further studies
are required to establish the antigen relationship with AFCo2 or
AFCo1 adjuvants and any advantages that this may confer in
inducing immunogenicity. However, the complexity of the
bacterial derived structures demand a greater understanding of
their composition and the rules leading to the assembly of
components, since this may provide information for improved
antigen loading efficiency.
FFEM confirms the multilayered nature (Figure 4A) of the
AFCo2 structure, but also the spiral formation, characteristic of
cochleates. Figure 4B shows the curvature of overlapping layers in
AFCo2, but it is difficult to identify a continuous bilayer forming
the structure. The cochleate phase represents by definition a single
bilayer curvature in only one direction [1–3]. Meyer et al. [13]
demonstrated that phosphatidylcholine/Ca cochleates alternate
convex-concave bilayer curvatures after cold-hydration. There-
fore, AFCo2 does not have the typical folding observed in previous
work [1–3,13]. However other authors have found that both
curved structures may be interrelated and convex-concave bilayer
deformations are observed after cochleate formation [14]. In
addition, Marone et al. [15] have described different supramolec-
ular structures formed as a result of different drug-, phospholipid-
or cation-interactions during cochleate formation; they showed
micrographs of cochleates with multilamellar rolled 1–5 mm
cylinders in 1,2-dioleoyl-sn-Glycero-3-[Phospho-L-Serine], spher-
ical indented rolled 200–300 nm particles with Soy phosphatidyl-
serine and planar 1 mm multilaminar sheets in palmitoyl-oleoyl
phosphatidylserine. These authors also found that treatment with
different cations such as calcium, magnesium, zinc, or barium
rendered different structural organization where continuity of
layers and also tubular shape was lost.
Another observation from the TEM results showed that smaller
vesicles where identified in the same preparation with the AFCo2.
Such findings are not new, and others have reported that
Table 2. Systemic and mucosal immune responses induced by mucosal immunization of AFCo2 or PLc in BALB/c mice.
Treatment Groups IgA IgG sera IgG2a/IgG1 Vibriocidal activity
IgA saliva IgA faeces
PLc (i.g) - - - - -
AFCo2 (i.g) 0.4860.12c 0.5560.15b - - -
Placebo (i.g) - - - - -
PLc (i.n) 0.6560.09b 0.4460.16b 2.960.14a 0.89 2.060.3a
AFCo2 (i.n) 0.9560.18a 0.7260.11a 3.160.09a 1.04 2.360.4a
Placebo (i.n) - - - - -
AFCo2 or PLc (100 mg) was administered by i.n or i.g route in BALB/c mice. Results of anti-PLc IgA in saliva and faeces and anti-PLc IgG in sera are expressed as the
logarithm of the mean 6 SEM. The ratio of IgG subclasses IgG2a/IgG1 is also reported. Vibriocidal activity of sera from immunized mice is also expressed as logarithm of
the mean 6 SEM. Statistical significance of the variance between multiple groups of experiments were calculated with one-way ANOVA, followed by a Tukey’s multiple
comparison test.
a,b,cDifferent letters on the same column mean that values are significantly different (p,0.05); - no response detected.
doi:10.1371/journal.pone.0046461.t002
Table 3. Systemic and mucosal anti-OVA IgA and IgG
response induced by intranasal immunization of AFCo2+ OVA
or PLc+OVA in BALB/c mice.
Treatment
Groups IgA IgG sera IgG2a/IgG1
IgA saliva IgA faeces
AFCo2+OVA 0.9360.12a 0.7860.16a 2.0160.18a 0.95
PLc+OVA 0.7460.14b 0.4460.14b 2.1260.2a 0.78
OVA 0.1960.08c 0.1560.07c - -
Placebo - - - -
AFCo2 or PLc (100 mg) was admixed with 20 mg of OVA and administered by i.n
route to BALB/c mice. Results are expressed as the logarithm of the mean 6
SEM. Statistical significance of the variance between multiple groups of
experiments were calculated with one-way ANOVA, followed by a Tukey’s
multiple comparison test.
a,b,cDifferent letters on the same column mean that values are significantly
different (p,0.05); - no response detected.
doi:10.1371/journal.pone.0046461.t003
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liposomes may coexist with cochleate structures obtained from
pure lipids [2–3,15], but in this context it appears as though the
vesicles are formed from the larger AFCo2 probably as a result of
the staining treatment and unfolding of the structure (Figure 2C).
To provide some understanding for this observation, we devised
an in vitro experiment (Figure 6 and Table 1) whereby AFCo2
cochleates were unfolded using EDTA (a calcium chelating agent).
The process was recorded and Video S1 is available as supporting
information. A white milky suspension (AFCo2) was transformed
into an opalescent colloidal solution consisting of vesicles of
50368.0 nm of size. This result emphasizes the importance of
calcium in the folding of AFCo2 into a cochleate structure, which
is very different to other elongated tubular structures, which are
not affected by the presence of the divalent cation [3].
Interestingly, the size of the re-folded vesicles (50368.0 nm) is
higher than the original structure (160.761.6 nm). This may be
due to some of the DOC detergent, used to re-suspend the
proteoliposomes during the cochleate preparation step, being
simultaneously entrapped. DOC from unfolded Co may become
incorporated into the vesicle membranes to increase their size and
may also be responsible for improving the immune response.
Barret et al. [16] demonstrated the adjuvant effect of DOC on
membrane protein antigen from HIV and with known absorption
enhancing properties may also increase the in vivo penetration of
antigens through the mucosal surface [17]. This could explain why
AFCo2 was more immunogenic than PLc when administered
mucosally (Table 2). However, the IgG2a/IgG1 induced by
AFCo2 showed to a bias towards IgG2a production, suggesting a
preferential induction of a Th1 type of immune response. This
response may be related to the difference in the size of both
structures. Particles exceeding 5 mm are considered optimal for
nasal application [18] and better retained within Peyer’s patches
[19]; anything smaller than this will travel to the lymphatics. This
suggests that the size of the antigen can determine the nature of an
immune response and that larger antigens held within local lymph
nodes may stimulate local mucosal immune responses while
smaller antigens, escaping to the peripheral lymphatics will induce
better systemic immune responses or tolerance [19–20]. We have
also shown that the size of lipid vesicles plays an important role in
Th1/Th2 bias in intragastric administration whereby particles
below a Z average of 250 nm induced a Th2 response and above a
Z average of 980 nm resulted in a Th1 response [21]. This effect
has been shown systemically to be a direct result of how small and
large lipid particles are trafficked to antigen presenting cell late
endosomes and early endosomes, respectively [22]. AFCo2 also
demonstrate to have an adjuvant effect to intranasally coadmin-
istered OVA at systemic and mucosal as well as affecting the
IgG2a/IgG1 ratio (Table 3). Then immunepotentiator and
delivery potentialities of cochleates derived from microorganism
[5] are also observed in AFCo2. Therefore, this study provides
further evidence for the influence on Th1/Th2 responses based on
lipid particle size used to present antigen.
Conclusions
Microscopic characterization disclosed that AFCo2 adopted
multilamellar, cochleate-like structures with the classic ‘‘spiral-
cochleate’’ pattern of overlapping layers, although no continuous
bilayers could be identified. Unlike previous studies we demon-
strated that the cochleate-like morphology of AFCo2 had aqueous
spaces within the structure that could accommodate additional
antigens and small molecules. AFCo2 were immunogenic follow-
ing intragastric administration and enhanced the immune
response to co-administered heterologous antigens when admin-
istered intranasally. Therefore, proteoliposome derived cochleate-
like structures such as AFCo2 provide potential to be a platform
adjuvant technology for the design of a wide range of multivalent
mucosal vaccine formulations. However, although AFCo2 is an
efficient immune activator, additional characterization is still
required before regulatory and commercial adoption. These
include standardization of adjuvant composition in particular the
LPS, outer membrane proteins and lipopeptide components of the
adjuvant derived from the microorganism, known to be ligands for
toll-like receptors and powerful activators of the immune system.
Nevertheless, since proteoliposomal and cochleate based formu-
lations have been used parenterally, with low toxicity, we expect
mucosal formulations to be equally viable. In addition, Perez et al.
demonstrated in 2006 [23] that a dose of 100 mg of PLc has less
than 3000 endotoxin units (EU) and the Neisseria proteoliposome
is approved for human use with less than 10 000 EU per dose by
the parenteral route. The next stages of reproducible manufac-
turing techniques including fermentation, extraction, purification
and processing will be critical in realising a product with suitable
attributes for regulatory approval. Work is presently continuing in
evaluating the importance of each of these parameters in adjuvant
optimisation. In parallel we are also exploring the incorporation of
heterologous and immunologically relevant antigens such as
Polysaccharide Vi of Salmonella Typhi in order to design a
multivalent vaccine against common enteric pathogens that offers
an alternative to the killed whole cell or live vaccines that are
currently available.
Supporting Information
Video S1 AFCo2 unfolding with EDTA. This video shows
the unfolding process of AFCo2 under the action of EDTA
chelating agent (25 mM). AFCo2 starts to shrinks in the first
15 seconds and completely disappears at 25 seconds of exposure
with EDTA.
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Acknowledgments
The authors are grateful to Prof James Alexander and Dr Arturo Talavera
for their advice and Anne Gowdie for technical assistance.
Author Contributions
Conceived and designed the experiments: RA OP LG ABM VAF.
Performed the experiments: RA CZ JLP AC BC DM. Analyzed the data:
RA OP CZ JLP AC BC VAF. Contributed reagents/materials/analysis
tools: OP VAF. Wrote the paper: RA ABM VAF.
References
1. Papahadjopoulos D, Vail WJ, Jacobson K, Poste G (1975) Cochleate lipid
cylinders: Formation of unilamellar lipid vesicles. Biochim Biophys Acta 394:
438–491.
2. Gould-Fogerite S, Kheiri MT, Zhang F, Wang Z, Scolpino AJ, et al. (1998)
Targenting immune response induction with cochleate and liposome based
vaccines. Advanced Drug Delivery Reviews 32: 273–287.
3. Zarif L (2002) Elongated supramolecular assemblies in drug delivery. Journal of
Controlled Release 81:7–23.
4. Pe´rez O, Bracho G, Lastre M, Sierra G, Campa C, et al. (2008) Method of
obtaining cochlear structures, vaccine compositions, adjuvants and intermediates
thereof. WIPO, WO/2004/047805. Granted by Cuban Office for Intellectual
Property OCPI23313.
Cochleates Derived from Vibrio cholerae O1
PLOS ONE | www.plosone.org 7 October 2012 | Volume 7 | Issue 10 | e46461
5. Pe´rez O, Lastre M, Cabrera O, del Campo J, Bracho G, et al. (2007) New
vaccines require potent adjuvants like AFPL1 and AFCo1. Scandinavian Journal
of Immunology 66: 271–277.
6. Acevedo R, Callico´ A, del Campo J, Gonza´lez E, Cedre´ B, et al. (2009)
Intranasal administration of proteoliposome-derived cochleates from Vibrio
cholerae O1 induce mucosal and systemic immune responses in mice. Methods
49: 309–315.
7. Qu X, Wei W, Gray AI, Tetley L, Uchegbu IF (2004) Self-assembly of cetyl
linear polyethylenimine to give micelles, vesicles, and dense nanoparticles.
Macromolecules 37: 9114–9122.
8. Yuki Y and Kiyono H (2009) Mucosal vaccines: novel advances in technology
and delivery. Expert Rev. Vaccines 8: 1083–1097.
9. Alcon V, Baca-Estrada M, Vega-Lopez M, Wilson P, Babiuk LA, et al. (2005)
Mucosal delivery of bacterial antigens and CpG oligonucleotides formulated in
biphasic lipid vesicles in pigs. AAPS Journal 7:E566–E571.
10. Ryan EJ, Daly LM, Mills KHG (2001) Immunomodulators and delivery systems
for vaccination by mucosal routes. Trends in Biotechnology 19: 293–304
11. Saptarshi P, Chaudhuria K, Chatterjee AN, Das J (1992) Presence of exposed
phospholipids in the outer membrane of Vibrio cholerae. Journal of General
Microbiology 138: 755–61.
12. Giles DK, Hankins JV, Guan Z, Trent MS (2011) Remodelling of the Vibrio
cholerae membrane by incorporation of exogenous fatty acids from host and
aquatic environments. Mol Microbiol 79:716–28
13. Meyer HW, Semmler K, Rettig W, Pohle W, Ulrich AS, et al. (2000) Hydration
of DMPC and DPPC produces a novel subgel phase with convex-concave
bilayer curvatures. Chem Phys Lipids 105: 149–166.
14. Garidel P, Richter W, Rapp G, Blume A (2001) Structural and morphological
investigations of the formation of quasi-crystalline phases of 1,2-dimyristoyl-sn-
glycero-3-phosphoglycerol (DMPG). Phys Chem Chem Phys 3: 1504–1513.
15. Marone PA, Elsmore SK, Sandulow J, Mannino RJ (2005) Structural
determinants of divalent cation-induced phosphatidylserine cochleate crystalli-
zation. Microsc Microanal 11:1244–1245.
16. Leng J, Egelhaaf SU, Cates ME (2003) Kinetics of the micelle-to-vesicle
transition: Aqueous lecithin-bile salt mixtures. Biophysical Journal 85: 1624–
1646.
17. Davis SS, Illum L (2003) Absorption enhancers for nasal drug delivery. Clin
Pharmacokinet; 42: 1107–1128.
18. Lewis D (2008) Mucosal Adjuvants. UK: St George’s Vaccine Institute.
Available: www.who.int/vaccineresearch/about/gvrf/Lewis.pdf.
19. Rimoldi M, Rescigno M (2005) Uptake and presentation of orally administered
antigens. Vaccine 23: 1793–1796.
20. Borges O, Lebre F, Bento D, Borchard G, Junginger HE (2010) Mucosal
Vaccines: Recent Progress in Understanding the Natural Barriers. Pharmaceu-
tical Research 27:211–23.
21. Mann JFS, Acevedo R, del Campo J, Perez O, Ferro VA (2009) Delivery
systems: a vaccine strategy for overcoming mucosal tolerance? Expert Rev
Vaccines 8: 103–112.
22. Brewer JM, Pollock KGJ, Tetley L, Russell DG (2004) Vesicle size influences the
trafficking, processing, and presentation of antigens in lipid vesicles. Journal of
Immunology 173:6143–50.
23. Pe´rez JL, Gonza´lez Y, An˜o G, Cedre´ B, Valmaseda T, et al. (2006) Obtaining
Vibrio cholerae 01 outer membrane extracts with different detergents.
VacciMonitor 15:1–7.
Cochleates Derived from Vibrio cholerae O1
PLOS ONE | www.plosone.org 8 October 2012 | Volume 7 | Issue 10 | e46461
